Remove Bioinformatics Remove Drugs Remove Genome Remove Protein
article thumbnail

CancerVar: A New Bioinformatics Tool Developed for Clinical Interpretation of Cancer Mutations

XTalks

On Saturday, researchers at the Children’s Hospital of Philadelphia (CHOP) have announced that they developed and launched a new bioinformatics software tool called CancerVar (cancer variant interpretation). Li, MD, Professor of Pathology and Laboratory Medicine, Director of Cancer Genomic Diagnostics. What is CancerVar?

article thumbnail

PanOmics: Advancing drug discovery

Drug Discovery World

The technologies cover the whole range of biomolecules from genes to protein to metabolites. While we are using standard commercially available processes for genomics, we have invested massively into high-throughput and high-resolution transcriptomics, proteomics, and metabolomics methods.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. Essentially, the collaboration brought together both “the right expertise and the right technology”, opening up myriad possibilities for targeting GPCRs within the human genome.

article thumbnail

Sensyne, Oxford University deploy AI to find asthma targets

pharmaphorum

Oxford University and UK clinical artificial intelligence (AI) company Sensyne Health will partner on a project to find new drug targets for people with hard-to-treat asthma. Dr Timothy Hinks. According to Hinks, “we still don’t understand the causes of asthma, because in the past the scientific tools just didn’t exist.

article thumbnail

Evotec Achieves Key Milestones in Its Collaboration with Bristol Myers Squibb On Targeted Protein Degradation

The Pharma Data

TWO NOVEL SOLID TUMOUR TARGETS FROM THE PARTNERSHIP TRANSITION INTO DRUG DISCOVERY. This has enabled the generation of a pipeline of novel first-in-class targeted protein degradation projects. Evotec will be responsible for progressing the drug discovery programmes to IND filing.

Protein 40
article thumbnail

Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s

pharmaphorum

It will attempt to validate the software by comparing its findings with clinical data such as brain imaging and genomics analyses to see if it can accurately detect neurocognitive impairments that can’t be found using current tests.

Trials 78
article thumbnail

Looking ahead to AACR  

Drug Discovery World

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Protein 52